Targeting harmful bacteria to improve treatment for gum disease
Evaluation of a microbiota-sparing therapeutic concept for periodontal disease, involving removal of pathogenic Porphyromonas and Fusobacterium
This study is exploring a new way to treat gum disease by targeting specific harmful bacteria while keeping the good bacteria in your mouth healthy, which could lead to better results and fewer complications for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas A&m University Health Science Ctr NIH-funded |
| Lab location | 1 site (College Station, United States) |
| Project ID | NIH-11222312 on NIH RePORTER |
What this research studies
This research investigates a new approach to treating periodontal disease by focusing on the harmful bacteria Porphyromonas gingivalis and Fusobacterium nucleatum. The goal is to develop a narrow-spectrum therapeutic agent that selectively eliminates these pathogens without disrupting the beneficial oral microbiota. By targeting a specific enzyme involved in bacterial fatty acid synthesis, the research aims to reduce inflammation and promote a healthier oral environment. Patients may benefit from improved treatment outcomes and reduced risk of complications associated with periodontal disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from chronic periodontal disease, particularly those with significant inflammation and bacterial infection.
Not a fit: Patients who do not have periodontal disease or those with advanced stages requiring surgical intervention may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for periodontal disease, reducing inflammation and preserving oral health.
How similar studies have performed: Previous research has shown promise in targeting specific bacterial pathogens in periodontal disease, suggesting that this approach could be effective.
Where this research is happening
College Station, United States
- Texas A&m University Health Science Ctr — College Station, United States (Active)
Researchers
- Principal investigator: Hurdle, Julian G — Texas A&m University Health Science Ctr
- Study coordinator: Hurdle, Julian G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.